BB Biotech AG (XSWX:BION) Debt-to-Asset : 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BION BB Biotech AG XSWX:BION
32 GF Score
Price CHF51.60
! 3 Warning Signs
View Full Analysis

What is BB Biotech AG Debt-to-Asset?

BB Biotech AG XSWX:BION -0.96% 32 Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus rates XSWX:BION with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

BB Biotech AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was CHF0 Mil. BB Biotech AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was CHF0 Mil. BB Biotech AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was CHF3,090 Mil. BB Biotech AG's debt to asset for the quarter that ended in Jun. 2026 was 0.00.

BB Biotech AG  (XSWX:BION) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BB Biotech AG Debt-to-Asset Related Terms

BB Biotech AG Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for BB Biotech AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG Debt-to-Asset Chart

BB Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.12 0.12 0.05 0.00

BB Biotech AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSWX:BION vs VRTX, REGN, RVMD: Debt-to-Asset Comparison

For the Biotechnology subindustry, BB Biotech AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BB Biotech AG Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Debt-to-Asset falls into.


XSWX:BION
32GF Score
BB Biotech AG XSWX:BION
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BB Biotech AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BB Biotech AG's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 2785.759
=0.00

BB Biotech AG's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 3089.778
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.00 mean?
BB Biotech AG (XSWX:BION) has a Debt-to-Asset of 0.00 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on BB Biotech AG and its competitors.
Is BB Biotech AG's Debt-to-Asset too high?
BB Biotech AG's current Debt-to-Asset is 0.00. Overall, BB Biotech AG has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Debt-to-Asset compare to VRTX and REGN?
BB Biotech AG's Debt-to-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on BB Biotech AG and its competitors. BB Biotech AG's current Debt-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current Debt-to-Asset of 0.00. The current Debt-to-Asset is 0.00. BB Biotech AG's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BB Biotech AG Business Description

Address Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
32GF Score

Get the complete analysis for XSWX:BION

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF51.60
Price